Last reviewed · How we verify
NCT05191498: SLOTH-1
Intratumoral Holmium Microspheres Brachytherapy for Patients With Pancreatic Cancer
NA trial testing QuiremSpheres® in Pancreas Cancer in 3 participants. Completed in 18 February 2024.
18 February 2024
Quick facts
| Lead sponsor | Radboud University Medical Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 3 |
| Start date | 13 December 2021 |
| Primary completion | 18 February 2024 |
| Estimated completion | 18 February 2024 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- QuiremSpheres®
Conditions studied
- Pancreas Cancer — all drugs for Pancreas Cancer →
Sponsor
Radboud University Medical Center
Who can join
18 and older, any sex, with Pancreas Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a feasibility study in which patients with pancreatic cancer are treated with intratumoral holmium microsphere injections.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Controlling T cell-tumor cell interaction with a biomimetic physical barrier for cancer immunotherapy.
Zhang Y, Wang J, Qing G, Wang Y, et al · · 2025 · cited 3× · PMID 40627401 · DOI 10.1073/pnas.2500589122
Verify or expand the search:
- PubMed search for NCT05191498
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of QuiremSpheres®
Trials testing the same drug.
- NCT04269499 — Real-time Imaging of Holmium Radioembolization: a Feasibility Study · NA · completed
Other recruiting trials for Pancreas Cancer
Currently open trials in the same condition.
- NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
- NCT07230509 — Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate · Phase 2 · recruiting
- NCT06926075 — Early Phase Study of KESONOTIDE™in Participants With Solid Tumours · Phase 1, PHASE2 · recruiting
- NCT07179692 — CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors · Phase 1 · recruiting
- NCT07132541 — Saleh's Technique for Pancreaticojejunostomy (Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate) · Phase 1 · recruiting
Other Radboud University Medical Center trials
Trials by the same sponsor.
- NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
- NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
- NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
- NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
- NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05191498 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
- Last refreshed: 11 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05191498.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing